Effects of Semaglutide on Weight and Insulin Requirements in Two Adolescents With Type 1 Diabetes

We present 2 case reports of the benefits of the subcutaneous once-weekly glucagon-like peptide 1 receptor agonist (GLP-1RA) therapy semaglutide in adolescents with type 1 diabetes (T1D) complicated by obesity. Two female individuals (17 and 12 years old) with T1D who have automated and continuous insulin delivery systems presented with marked weight gain, increasing insulin requirement, and suboptimal glycemic control. We added GLP-1RA to standard insulin pump therapy and revisited education re